<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="167605">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915590</url>
  </required_header>
  <id_info>
    <org_study_id>09-03-017</org_study_id>
    <nct_id>NCT00915590</nct_id>
  </id_info>
  <brief_title>Topical IL-1-Ra for Treatment of Corneal Neovascularization</brief_title>
  <official_title>Topical IL-1-Ra for Treatment of Corneal Neovascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of topical
      Interleukin-1-Receptor Antagonist in treatment of corneal neovascularization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the extent of corneal NV at Week 6, 12, 24 and 64 by measurement of: Neovascular Area (NA) Vessel Caliber (VC) Invasion Area (IA)</measure>
    <time_frame>64 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity (BSCVA) at Week-6, 12, 24, 64 and central corneal thickness at Week-6, 12, 24, 64</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Corneal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients will complete a course of treatment with placebo, followed by a course of treatment with 5% custom made topical IL-1Ra.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients will complete a course of treatment with 5% custom made topical IL-1Ra, followed by a course of treatment with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Custom eye drop eye three times a day in both eyes for a period of 6 weeks</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-1Ra</intervention_name>
    <description>5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 18 years

          -  Patients with superficial or deep corneal NV that extends farther than 1 mm from the
             limbus

          -  Patients are in generally good stable overall healthExclusion Criteria: • Has
             received treatment with anti-VEGF agents (topical, intraocular or systemic) within 30
             days of study entry

          -  Corneal or ocular surface infection within 30 days prior to study entry• Ocular or
             periocular malignancy

          -  Contact lens (excluding bandage contact lens) use within 2 weeks prior to study entry

          -  Persistent epithelial defect (&gt;1mm and ≥14 days duration) within 2 weeks prior to
             study entry

          -  Intravitreal or periocular steroids within 2 weeks prior to study entry

          -  Change in dose/frequency of topical steroids and/or NSAIDs within 2 weeks prior to
             study entry

          -  Pregnancy (positive pregnancy test) or lactation

          -  Premenopausal women not using contraception

          -  Signs of current infection, including fever and current treatment with antibiotics

          -  Participation in another simultaneous medical investigation or trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 19, 2012</lastchanged_date>
  <firstreceived_date>June 4, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Corneal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
